meRfi®-GM
Colibactin-Producing Escherichia coli / E. coli pks+
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Colibactin-Producing Escherichia coli / E. coli pks + could promote a procarcinogenic immune environment through impairment of antitumor T-cell response, leading to tumoral resistance to immunotherapy
E. coli harboring the pathogenicity island pks (also called clb), encoding the enzymes that produce colibactin.
Pleguezuelos-Manzano et al. 2020a CANCER DISCOVERY 10: 635
Colibactin-Producing Escherichia coli / E. coli pks + are present in a substantial fraction of individuals (about 20% of healthy individuals, about 40% of patients with [inflammatory bowel disease](brain://H7D15HzlkkC7QHg6z4HOrA/EColiPks…
References (Sources)
- Autophagy of Intestinal Epithelial Cells Inhibits Colorectal Carcinogenesis Induced by Colibactin-Producing Escherichia Coli in ApcMin/+ Mice
- Colibactin causes colorectal cancer-associated mutational signature
- Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer
- Colibactin-Producing Escherichia coli Induce the Formation of Invasive Carcinomas in a Chronic Inflammation-Associated Mouse Model
- High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer
- Insights into the acquisition of the pks island and production of colibactin in the Escherichia coli population
- Molecular epidemiology and phylogenetic distribution of the Escherichia coli pks genomic island